Alnylam Pharmaceuticals | ALNY - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Arrowhead Research USD 465.53M 148.45M 2026-06
BioCryst Pharmaceuticals USD -454.29M 99.55M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Incyte USD 6.34B 721.58M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
Moderna USD 6.76B 647M 2026-06
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 38.93B 7.2B 2026-03
PTC Therapeutics USD -165.36M 15.1M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 73.14B 1.43B 2026-03
Sarepta Therapeutics USD 1.53B 22.7M 2026-06
Takeda JPY 7.56T 215.7B 2026-06
Tectonic Therapeutic USD 230.42M 20.91M 2026-03
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Vertex Pharmaceuticals USD 20.25B 886M 2026-06
Xencor USD 503.23M 12.4M 2026-06